Intrinsic adjuvanting of a novel single-cycle flavivirus vaccine in the absence of type I interferon receptor signaling

Vaccine

Volumn 30, Issue 8, 2012, Pages 1465-1475

  Winkelmann, Evandro R ^a   Widman, Douglas G ^a,d   Xia, Jingya ^a,e   Ishikawa, Tomohiro ^a   Miller Kittrell, Mindy ^b   Nelson, Michelle H ^a   Bourne, Nigel ^a,c   Scholle, Frank ^b   Mason, Peter W ^a,f   Milligan, Gregg N ^a,c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

^f Microbial Molecular Biology   (United States)

Author keywords

CD8 + T cell; Single cycle virus; Type I IFN; West Nile virus

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERFERON RECEPTOR; WEST NILE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; INTERFERON INDUCTION; INTERFERON PRODUCTION; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRUS INHIBITION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOGLOBULIN G; LYMPH NODES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; WEST NILE FEVER; WEST NILE VIRUS VACCINES;

EID: 84856586259     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.103     Document Type: Article

References (45)

1. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 2006, 103(April (17)):6694-6699.
2. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006, 2(March-April (2)):60-67.
3. Lieberman M.M., Nerurkar V.R., Luo H., Cropp B., Carrion R., de la Garza M., et al. Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin Vaccine Immunol 2009, 16(September (9)):1332-1337.
4. Martin J.E., Pierson T.C., Hubka S., Rucker S., Gordon I.J., Enama M.E., et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007, 196(December (12)):1732-1740.
5. Widman D.G., Ishikawa T., Fayzulin R., Bourne N., Mason P.W. Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system. Vaccine 2008, 26(May (22)):2762-2771.
6. Mason P.W., Shustov A.V., Frolov I. Production and characterization of vaccines based on flaviviruses defective in replication. Virology 2006, 351(August (2)):432-443.
7. Widman D.G., Ishikawa T., Winkelmann E.R., Infante E., Bourne N., Mason P.W. RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters. Vaccine 2009, 27(September (41)):5550-5553.
8. Widman D.G., Ishikawa T., Giavedoni L.D., Hodara V.L., Garza Mde L., Montalbo J.A., et al. Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection. Am J Trop Med Hyg 2010, 82(June (6)):1160-1167.
9. Le Bon A., Tough D.F. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002, 14(August (4)):432-436.
10. Randall R.E., Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008, 89(January (Pt 1)):1-47.
11. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14(April (4)):461-470.
12. Prchal M., Pilz A., Simma O., Lingnau K., von Gabain A., Strobl B., et al. Type I interferons as mediators of immune adjuvants for T- and B cell-dependent acquired immunity. Vaccine 2009, (December (27 Suppl. 6)):G17-G20.
13. Proietti E., Bracci L., Puzelli S., Di Pucchio T., Sestili P., De Vincenzi E., et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 2002, 169(July (1)):375-383.
14. Gilfoy F., Fayzulin R., Mason P.W. West Nile virus genome amplification requires the functional activities of the proteasome. Virology 2009, 385(March (1)):74-84.
15. Rossi S.L., Zhao Q., O'Donnell V.K., Mason P.W. Adaptation of West Nile virus replicons to cells in culture and use of replicon-bearing cells to probe antiviral action. Virology 2005, 331(January (2)):457-470.
16. Banks T.A., Rickert S., Benedict C.A., Ma L., Ko M., Meier J., et al. A lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection. J Immunol 2005, 174(June (11)):7217-7225.
17. Bourne N., Scholle F., Silva M.C., Rossi S.L., Dewsbury N., Judy B., et al. Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production. J Virol 2007, 81(September (17)):9100-9108.
18. Nelson M.H., Winkelmann E., Ma Y., Xia J., Mason P.W., Bourne N., et al. Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine. Vaccine 2010, 29(December (2)):174-182.
19. Purtha W.E., Myers N., Mitaksov V., Sitati E., Connolly J., Fremont D.H., et al. Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. Eur J Immunol 2007, 37(July (7)):1845-1854.
20. Brien J.D., Uhrlaub J.L., Nikolich-Zugich J. Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection. Eur J Immunol 2007, 37(July (7)):1855-1863.
21. Brien J.D., Uhrlaub J.L., Nikolich-Zugich J. West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection. J Immunol 2008, 181(December (12)):8568-8575.
22. Jia T., Leiner I., Dorothee G., Brandl K., Pamer E.G. MyD88 and Type I interferon receptor-mediated chemokine induction and monocyte recruitment during Listeria monocytogenes infection. J Immunol 2009, 183(July (2)):1271-1278.
23. Cremer I., Ghysdael J., Vieillard V. A non-classical ISRE/ISGF3 pathway mediates induction of RANTES gene transcription by type I IFNs. FEBS Lett 2002, 511(January (1-3)):41-45.
24. Malmgaard L., Salazar-Mather T.P., Lewis C.A., Biron C.A. Promotion of alpha/beta interferon induction during in vivo viral infection through alpha/beta interferon receptor/STAT1 system-dependent and -independent pathways. J Virol 2002, 76(May (9)):4520-4525.
25. Guarda G., Braun M., Staehli F., Tardivel A., Mattmann C., Forster I., et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011, 34(February (2)):213-223.
26. Jego G., Palucka A.K., Blanck J.P., Chalouni C., Pascual V., Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19(August (2)):225-234.
27. Havenar-Daughton C., Kolumam G.A., Murali-Krishna K. Cutting edge: the direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J Immunol 2006, 176(March (6)):3315-3319.
28. Curtsinger J.M., Valenzuela J.O., Agarwal P., Lins D., Mescher M.F. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005, 174(April (8)):4465-4469.
29. Coro E.S., Chang W.L., Baumgarth N. Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection. J Immunol 2006, 176(April (7)):4343-4351.
30. Slifka M.K., Matloubian M., Ahmed R. Bone marrow is a major site of long-term antibody production after acute viral infection. J Virol 1995, 69(March (3)):1895-1902.
31. Kolumam G.A., Thomas S., Thompson L.J., Sprent J., Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 2005, 202(September (5)):637-650.
32. Thompson L.J., Kolumam G.A., Thomas S., Murali-Krishna K. Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation. J Immunol 2006, 177(August (3)):1746-1754.
33. Daffis S., Samuel M.A., Suthar M.S., Gale M., Diamond M.S. Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol 2008, 82(November (21)):10349-10358.
34. Wang T., Town T., Alexopoulou L., Anderson J.F., Fikrig E., Flavell R.A. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004, 10(December (12)):1366-1373.
35. Town T., Bai F., Wang T., Kaplan A.T., Qian F., Montgomery R.R., et al. Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. Immunity 2009, 30(February (2)):242-253.
36. Fredericksen B.L., Keller B.C., Fornek J., Katze M.G., Gale M. Establishment and maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and MDA5 signaling through IPS-1. J Virol 2008, 82(January (2)):609-616.
37. Marrack P., Kappler J., Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999, 189(February (3)):521-530.
38. Sanchez V., Gimenez S., Tomlinson B., Chan P.K., Thomas G.N., Forrat R., et al. Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 2006, 24(June (23)):4914-4926.
39. Braun D., Caramalho I., Demengeot J. IFN-alpha/beta enhances BCR-dependent B cell responses. Int Immunol 2002, 14(April (4)):411-419.
40. Purtha W.E., Chachu K.A., Virgin H.Wt., Diamond M.S. Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. J Virol 2008, 82(November (22)):10964-10974.
41. Fink K., Lang K.S., Manjarrez-Orduno N., Junt T., Senn B.M., Holdener M., et al. Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses. Eur J Immunol 2006, 36(August (8)):2094-2105.
42. Dondi E., Rogge L., Lutfalla G., Uze G., Pellegrini S. Down-modulation of responses to type I IFN upon T cell activation. J Immunol 2003, 170(January (2)):749-756.
43. Valenzuela J., Schmidt C., Mescher M. The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. J Immunol 2002, 169(December (12)):6842-6849.
44. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev 2008, 8(April (4)):247-258.
45. Wherry E.J., Blattman J.N., Murali-Krishna K., van der Most R., Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003, 77(April (8)):4911-4927.